MTOR and anemia (phenotype): In addition, the reported hematological AEs were known and also common, such as neutrophil count decreased, white blood cell decreased, lymphocyte count decreased, anemia and platelet count decreased, similar to CHOP regimen, CHOP-like regimen or novel antineoplastic agent (denileukin diftitox [a genetically engineered fusion protein], azacitidine [an epigenetic modifier], and everolimus [an mTOR inhibitor]) plus CHOP regimen (21–24).